Are you optimizing
clinical intelligence?

The right data and strategic insights are often elusive. That is why MDCPartners takes deeper dives for our clients in the pharmaceutical and medical industries. By merging our business expertise with unique IT platforms and portals we can fully support your intelligence and business needs for clinical trial optimization, medical expert identification, and regulatory compliance.

Strategic data advances clinical development

MDCPartners is dedicated to providing tools and services to help pharmaceutical companies make better decisions. Our flagship product, ta-Scan, is a web-based data platform that helps users monitor, aggregate, and analyze regulatory data, trial data, and expert profiles. Whether you need to optimize study placement, select research partners, or manage your portfolios, our products and portals will help you bridge the information gaps in today’s competitive clinical research environment.

Learn more about ta-Scan 5

Are your medical devices meeting standards?

To support manufacturers of medical devices and in vitro diagnostics (IVDs), MDCPartners has developed normScan, a web-based standards tracking tool tailored to your product range. It can also help you obtain regulatory approval for marketing products throughout Europe, and can assist you with a broad spectrum of regulatory issues related to maintaining compliance.

Learn more about normScan

Bring your own data, use our know-how

MDCPartners doesn’t just offer tools for visualizing public data. We also provide tools for depicting external client data merged with information from our public data cloud. So if you have specific needs that surpass the scope of ta-Scan, you can still rely on us for tailor-made real world data solutions.

Learn more about our data solutions

Latest News & Events

ta-Scan SCOPE Europe 2018 Barcelona

SCOPE Europe 2018: Join us at the First European Edition

Join us in October at the inaugural edition of SCOPE Europe in Barcelona, Spain. Visit the ta-Scan team at booth #6 or make an appointment with our attendees:

Chairperson’s Remarks

David Cocker, CSO, ta-Scan Business Intelligence Systems, MDCPartners

DAY 1, Tuesday 16 October, 13:55h
David Cocker, Chief Scientific Officer, ta-Scan Business Intelligence Systems, MDCPartners / Anju Software
Track 1: Analytics-Driven Feasibility, Site Selection and Study Activation

 

 

About SCOPE Europe

Building on the success of its long-running US-based counterpart, Summit for Clinical Trials Operations Executives Europe (SCOPE Europe) is a two-day event serving clinical operations executives, functional heads, category managers and those responsible for the planning and management of clinical trials in Europe and the rest of the world. The event will feature opening and closing plenary keynote sessions, three conference tracks, interactive breakout discussion groups and networking. It is an opportunity for leaders from large, mid-sized, and small pharma, specialty pharma, biotech, vendor companies, and academic research centers to come together to share best practices and discuss the new era of analytics-driven and patient-centric trials. Topics to be discussed include protocol development, global site selection, feasibility, site management, patient engagement, enrollment planning, patient recruitment, patient retention, improving site-study activation and performance, functional/full-service outsourcing and partnerships, new regulations and guideline, Risk-Based Monitoring (RBM), and improving overall quality and speed of clinical trials.

Register to join us

Have a look at the agenda: http://www.scopesummiteurope.com/2018-brochure-download-form

Register here to join us in Barcelona: https://chidb.com/reg/scoe/reg.asp

We hope to see you there!

Share on:
Tweet about this on Twitter
Twitter
Share on LinkedIn
Linkedin

Anju Software Continues to Build the Next Generation Life Science Software and Data Platform Through Acquisition of MDCPartners

NEW YORK–Anju Software Inc., a life sciences software platform backed by Providence Equity Partners, has acquired Antwerp-based MDCPartners, a company that specializes in business intelligence data solutions for clinical trial optimization, medical expert identification and competitive intelligence.

“MDCPartners will enable Anju to provide additional value added solutions to pharmaceutical, biotech and medical device companies. This acquisition strengthens Anju’s current product portfolio and can now provide up-to-date comprehensive data for Medical Expert Engagement and Clinical Trial Optimization. MDC, which is based in Belgium, also provides us with operations in Europe to better service our global customers,” said Mr. Kurien Jacob, CEO of Anju Software.

“Anju’s approach and philosophy provides us with financial strength and scale as well as additional resources to support our growth strategy and guide our clients over the long-term,” added Mireille De Cré, co-founder and CEO of MDCPartners.

“With the acquisition of MDCPartners, Anju continues its accelerated growth within the Medical Affairs and clinical trial sectors. Anju is now recognized as an emerging leader in the life science software industry, providing end-to-end software solutions that help customers manage mission critical pharma processes and turn data into actionable insights. We continue to be impressed with what the Anju management team, led by CEO Kurien Jacob, has been able to achieve in a short period of time,” said Gopi Vaddi, Managing Director of Providence Strategic Growth.

Snell and Wilmer acted as legal counsel to Anju and Madison Park Group acted as financial advisors to Anju on the transaction.

About Anju Software

Anju Software is a leading provider of comprehensive software solutions to the life sciences industry. The Company provides an integrated platform spanning clinical, medical affairs and after-market functions for pharmaceutical, biotech and medical device companies and clinical research organizations. Anju was founded by a group of operating professionals with deep software domain expertise and intent on building the next generation platform for the life sciences sector. Over the past two years, Anju has acquired five companies:

  • Online Business Applications – Market leader in medical information solutions and pharmacovigilance
  • OpenQ – Solutions for key opinion leader (KOL) engagement and management
  • ClinPlus – Provider of comprehensive electronic data capture (EDC), clinical trials management software (CTMS), electronic trial master file (eTMF) solutions
  • Sylogent – Clinical data capture and publishing planning solutions
  • MDCPartners – Business intelligence solutions

Anju Software is a portfolio company of Providence Strategic Growth, the growth equity affiliate of Providence Equity Partners, a global private equity firm with over $57 billion in capital under management.

About MDCPartners

MDCPartners provides business intelligence solutions for clinical trial optimization, medical expert identification and competitive intelligence. With deep expertise in the fields of data mining, semantic processing and engineering, MDC provides its clients with event-based tools to monitor and analyze an ever-expanding world of public and private data. With their proprietary data solutions, users can transform millions of scattered data points into a robust snapshot of a therapeutic area. MDC combines its expertise in drug development processes with its unique IT architecture to provide cost effective information solutions to the pharmaceutical and biotech industry. MDCPartners offers a product suite that includes: ta-Scan, a web-based data platform that helps users monitor, aggregate, and analyze regulatory data, trial data and expert profiles; normScan: web-based standards tracking tool tailored to clients’ product range; and Real World Solutions; a tool allowing the depiction of external client data merged with information from a public data cloud.

About Providence Equity

Providence is a premier global private equity firm with more than $57 billion in capital under management. Providence pioneered a sector-focused approach to private equity investing with the vision that a dedicated team of industry experts could build exceptional companies of enduring value. Since the firm’s inception in 1989, Providence has invested in more than 160 companies and is a leading equity investment firm focused on the media, communications, education and information industries. Providence is headquartered in Providence, RI, and also has offices in New York and London. For more information, please visit www.provequity.com.

Contacts

Anju Software
Kurien Jacob, +1 480-326-2358
kurien@anjusoftware.com

MDCPartners
Mireille De Cré
mireille.decre@mdcpartners.be

Providence Equity 
Sard Verbinnen & Co
Andrew Cole / Kelsey Markovich
Prov-SVC@SARDVERB.COM
+1 212-687-8080

View Business Wire press release: https://www.businesswire.com/news/home/20180621005656/en/Anju-Software-Continues-Build-Generation-Life-Science

Share on:
Tweet about this on Twitter
Twitter
Share on LinkedIn
Linkedin
DIA Europe 2018 ta-Scan David Cocker

Celebrate the 30th DIA Europe with us in Basel!

The second meeting the ta-Scan team has in store for April is nothing less than the 30th edition of the DIA Europe 2018 meeting. That deserves a celebration!

Join us in Basel

If you want to get a demo of our clinical business intelligence solution ta-Scan and our newest developments, or learn more about our other (custom) software solutions, visit us at DIA Europe 2018 at booth #100 or make an appointment with the ta-Scan team:

You can register here.

DIA Europe 2018

2018 marks the 30th anniversary of the DIA EuroMeeting. To support this anniversary, and to align this European flagship meeting with all the DIA regional flagship meetings occurring across the globe, we are renaming the gathering, DIA Europe 2018. This new name reflects not only regional alignment but also a change in approach to more directly and proactively focus on the expressed needs and interests of our constituents. DIA Europe 2018 is more than just a traditional meeting. It’s a chance to learn, engage, and grow as a professional in health care.

We convene these platforms around the globe, from the DIA Global Annual Meeting in the United States, to regional meetings in China, Europe, India and Japan, to provide you with a neutral forum to discuss current issues, with the goal of uncovering new ways of working and new solutions for patients. We welcome participants from across the entire drug development industry. By incorporating representatives from the full life sciences landscape we facilitate open collaboration. We ensure that industry, payors, patients and regulators, all have an equal voice.

We look forward to welcoming everyone to DIA Europe’s home in Basel, Switzerland. Download the meeting programme here.

Share on:
Tweet about this on Twitter
Twitter
Share on LinkedIn
Linkedin

Downloads

  • Introduction to ta-Scan

    Get to know ta-Scan better with this general introduction fact sheet.

    US Letter Format | A4 Format
  • ta-Scan for Clinical Trial Planning & Site Selection

    Learn how to use ta-Scan for clinical trial planning and site selection in this fact sheet.

    US Letter Format | A4 Format
  • ta-Scan for Expert Profiling & Medical Affairs

    Learn how to use ta-Scan for expert profiling and medical affairs.

    US Letter Format | A4 Format
  • ta-Scan for Competitive Intelligence & Disease Landscapes

    Learn how to use ta-Scan for competitive intelligence and disease landscapes in this fact sheet.

    US Letter Format | A4 Format
  • ta-Scan's Trial Feasibility Wizard

    Find out more information about ta-Scan's Trial Feasibility Wizard in this fact sheet.

    US Letter Format | A4 Format

Connect with MDCPartners

Follow us on LinkedIn

Follow us on Twitter

Top of Page